Last week, the FDA announced a transformative shift in drug development policy that monoclonal antibody (mAb) therapeutics may no longer require testing in animal models. Instead, the agency is endorsing next-generation approaches such as AI modelling and lab-grown human organoids designed to more accurately predict human responses and accelerate the path to clinical success.
